Premium
A long‐term efficacy of allogeneic bone marrow mesenchymal stem cells in myocardial repair
Author(s) -
Huang XiPing,
Sun Zhao,
Miyagi Yasuo,
Zhang Li,
Weisel Richard,
Li RenKe
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.lb436
Subject(s) - mesenchymal stem cell , immune system , medicine , immunology , stem cell , bone marrow , transplantation , biology , pathology , microbiology and biotechnology
Allogeneic mesenchymal stem cells (AMSCs) are currently undergoing clinical trials for myocardial repair. However, their long‐term therapeutic efficacy has not been established. We conducted a six month comparative study on allogeneic and syngeneic MSCs using a MI rat model. We found AMSCs were immunoprivileged soon after implantation and produced a robust cardiac functional improvement similar to syngeneic MSCs in the first three months after treatment. After two weeks implantation, the differentiated AMSCs acquired immunogenic phenotype associated with increased cell surface expression of MHC class I and II molecules, rendering them immune rejected and diminishing their ability to prevent heart failure after 6 months of treatment. These results suggest that AMSCs have short‐term benefits for heart repair, and reconcile inconsistent findings from earlier studies by identifying the unknown biphasic immune response to AMSCs. Differentiation induced immune rejection supports the need for future studies to modify the late immunogenic phenotype of MSCs to prevent rejection and achieve long term benefits of AMSCs for cardiac repair. Supported by HSFO and CIHR.